Compare Msci Inc (MSCI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Msci Inc trades at $562.51 (market cap $45.51B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: Msci Inc pays a 1.31% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Msci Inc nearer its low. Which is the better fit depends on your goals.
| MSCI | XBI | |
|---|---|---|
Market Cap | $45.51B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $643.83 | $164.28 |
52-Week Low | $511.84 | $85.16 |
Enterprise Value | $51.67B | — |
Dividend Yield | 1.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI is trading at $561.74, down 10.64% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company reported Q2 2026 EPS of $4.94, exceeding estimates of $4.90, driven by recurring subscription growth and ETF-linked AUM. Technical indicators show a bullish trend with key support at $606, while valuation ratios remain elevated with a P/E of 35.7. Recent strategic partnerships with UBS and the acquisition of First Street enhance its private markets and climate risk capabilities.
Outlook remains positive with 73% analyst buy ratings and a $725.44 consensus price target, implying 29% upside. Risks include high debt levels ($4.51B) and competitive pressures in financial data services. The stock offers growth potential through innovation and market expansion, but investors should monitor execution on strategic initiatives and margin sustainability amid economic uncertainties.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
